# US 2026/0062497 A1 · Pharmaceutical Formulation and Dosing Regimen for the Treatment of Amyotrophic Lateral Sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062497 A1
- Document ID: US20260062497A1
- Status: Published application
- Kind: A1
- Application number: 19/106,573
- Filed: 2023-08-28
- Published: 2026-03-05
- Earliest claimed: 2022-08-26
- Assignees: AL-S Pharma AG
- Applicants: AL-S Pharma AG
- Inventors: Marcel MAIER; Michael SALZMANN; Angela GENGE
- Web page: https://patentgrep.com/patent/US20260062497A1

## CPC

- C07K 16/40: against enzymes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).

## Claims

### Claim 1

A recombinant antibody that selectively binds to misfolded and/or aggregated forms of superoxide dismutase (SOD1) for use in the treatment of amyotrophic lateral sclerosis (ALS), wherein the treatment comprises administration of a dose of the antibody of about 2500 mg to a patient in need thereof.

### Claim 2 (depends on 1)

The antibody for use according to claim 1, wherein the antibody is administered once every 3 weeks.

### Claim 3 (depends on 1, 2)

The antibody for use according to claim 1 or 2, wherein the antibody is administered via intravenous (IV) infusion.

### Claim 4 (depends on 1, 2, 3)

The antibody for use according to any of claims 1 to 3, wherein the patient receives a loading dose of the antibody of about 500 mg, followed on the other day by a dose of the antibody of 2500 mg prior to the administration of the antibody once every 3 weeks.

### Claim 5 (depends on 1, 2, 3, 4)

The antibody for use according to any one of claims 1 to 4, wherein administration of the antibody will take place once every 3 weeks for at least a 6-month period.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody for use according to any one of claims 1 to 5, wherein the antibody is administered at a concentration of about 20 mg/mL.

### Claim 7 (depends on 6)

The antibody for use according to claim 6, wherein the antibody is administered over a period of min. 60 and max. 120 minutes.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The antibody for use according to any one of claims 1 to 7, wherein the patient suffers from familial amyotrophic lateral sclerosis (fALS).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The antibody for use according to any one of claims 1 to 7, wherein the patient suffers from sporadic amyotrophic lateral sclerosis (sALS).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antibody for use according to any one of claims 1 to 9, wherein the patient receives riluzole, edaravone, a combination of sodium phenylbutyrate and tauroursodeoxycholic acid (PB and TUDCA) or Tofersen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The antibody for use according to any one of claims 1 to 10, wherein, if infusion reactions are observed, 500 to 1000 mg acetaminophen, and/or an antihistamine may be administered orally or IV 30 to 60 minutes prior to the start of infusion for subsequent dose administrations.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The antibody for use according to any one of claims 1 to 11, wherein the therapeutic effect of the antibody and progression of ALS is monitored by assessing one or more biomarkers.

### Claim 13 (depends on 12)

The antibody for use according to claim 12, wherein the biomarkers are selected from the group consisting of phospho-neurofilament heavy chain (pNfH), neurofilament light chain (NfL) and misfolded SOD1 (mSOD1).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The antibody for use according to any one of claims 1 to 13, wherein the antibody binds to an epitope of SOD1 within the amino acid sequence 73-GGPKDEERHVGD-84 set forth in SEQ ID NO: 11.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The antibody for use according to any one of claims 1 to 14, wherein the antibody is characterized by comprising in its variable region, i.e., binding domain the six CDRs of the variable heavy (VH) and variable light (VL) chain, wherein:
(a) VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 3 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(b) VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 4 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(c) VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 5 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(d) VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 8 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(e) VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 9 or a variant thereof, wherein the variant comprises one or two amino acid substitutions, and
(f) VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 10 or a variant thereof, wherein the variant comprises one or two amino acid substitutions.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The antibody for use according to any one of claims 1 to 15, wherein the antibody is characterized by comprising in its variable region, i.e., binding domain a VH chain and a VL chain, wherein
(a) the VH chain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence depicted in SEQ ID NO: 1 or 2; and
(b) the VL chain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence depicted in SEQ ID NO: 6 or 7.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The antibody for use according to any one of claims 1 to 16, wherein the antibody comprises a human Ig constant region.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The antibody for use according to any one of claims 1 to 17, wherein the antibody is a human IgG.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The antibody for use according to any one of claims 1 to 18, wherein the antibody a human IgG1.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The antibody for use according to any one of claims 1 to 19, wherein the antibody is a human IgG1m3 allotype.

### Claim 21 (depends on 18, 19, 20)

The antibody for use according to any one of claims 18 to 20, wherein the antibody comprises a kappa (κ) or lambda (λ) light chain.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The antibody for use according to any one of claims 1 to 21, wherein the antibody is AP-101 and a human IgG1m3 allotype.

### Claim 23 (depends on 22)

The antibody for use according to claim 22, wherein each heavy chain is comprised of 453 amino acid residues having SEQ ID NO: 12, and each light chain is comprised of 213 amino acid residues having SEQ ID: 13.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The antibody for use according to any one of claims 1 to 23, which is produced in CHO-K1 host cells and purified from the cell culture.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The antibody for use according to any one of claims 16 to 24, wherein the heavy chain of the antibody is undergoing N-terminal glutaminyl cyclization.

### Claim 26 (depends on 9, 10)

The antibody for use according to claim 9 or 10, wherein the heavy chain is undergoing C-terminal lysine clipping.

### Claim 27 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The antibody for use according to any one of claims 16 to 26, which is N-glycosylated.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The antibody for use according to any one of claims 1 to 27, wherein the antibody is administered in a formulation of any one of claims 29 to 47.

### Claim 29

A liquid aqueous formulation of a recombinant antibody as defined in any one of the preceding claims that selectively binds to misfolded and/or aggregated forms of superoxide dismutase (SOD1), wherein the formulation is suitable for intravenous administration and comprises the antibody at a concentration of about 10 to 50 mg/ml in a L-histidine/L-histidine monohydrochloride buffer at a pH of about 6.0±1, wherein the antibody remains stable at 5° C.±2° C. for at least 1 month, at 25° C.±2° C. for at least 1 month, and/or at 40° C.±2° C. for 1 week.

### Claim 30 (depends on 29)

The formulation of claim 29, wherein the antibody is characterized by comprising in its variable region, i.e., binding domain the six CDRs of the variable heavy (VH) and variable light (VL) chain, wherein:
(a) VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 3 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(b) VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 4 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(c) VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 5 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(d) VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 8 or a variant thereof, wherein the variant comprises one or two amino acid substitutions,
(e) VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 9 or a variant thereof, wherein the variant comprises one or two amino acid substitutions, and
(f) VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 10 or a variant thereof, wherein the variant comprises one or two amino acid substitutions; and
wherein the antibody comprises a human Ig constant region.

### Claim 31 (depends on 29, 30)

The formulation of claim 29 or 30, wherein the antibody is characterized by comprising in its variable region, i.e., binding domain a VH chain and a VL chain, wherein
(a) the VH chain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence depicted in SEQ ID NO: 1 or 2; and
(b) the VL chain comprises an amino acid sequence which is at least 90% identical to the amino acid sequence depicted in SEQ ID NO: 6 or 7.

### Claim 32 (depends on 29, 30, 31)

The formulation of any one of claims 29 to 31, wherein the antibody binds to an epitope of SOD1 within the amino acid sequence 73-GGPKDEERHVGD-84 set forth in SEQ ID NO: 11.

### Claim 33 (depends on 29, 30, 31, 32)

The formulation of any one of claims 29 to 32, wherein the antibody is a human IgG.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The formulation of any one of claims 29 to 33, wherein the antibody a human IgG1.

### Claim 35 (depends on 29, 30, 31, 32, 33, 34)

The formulation of any one of claims 29 to 34, wherein the antibody is human IgG1m3 allotype.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The formulation of any one of claims 31 to 35, wherein the antibody comprises a kappa (κ) or lambda (λ) light chain.

### Claim 37 (depends on 35, 36)

The formulation of claim 35 or 36, wherein each heavy chain is comprised of 453 amino acid residues having SEQ ID NO: 12, and each light chain is comprised of 213 amino acid residues having SEQ ID: 13.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The formulation of any one of claims 29 to 37, which is produced in CHO-K1 host cells and purified from the cell culture.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The formulation of any one of claims 29 to 38, wherein the antibody is AP-101.

### Claim 40 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The formulation of any one of claims 31 to 39, wherein the antibody is composed of two heavy chains having SEQ ID NO: 12, and two light chains having SEQ ID: 13, optionally wherein in the heavy chain the glutamine at the N-terminus is modified as pyro-glutamic acid and the C-terminal lysine is lost, and wherein the heavy chain is N-glycosylated.

### Claim 41 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The formulation of any one of the claims 29 to 40, wherein the antibody is present at a concentration of 20±5 mg/mL.

### Claim 42 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The formulation of any one of claims 29 to 41, wherein the concentration of L-histidine/L-histidine monohydrochloride is 20±10 mM.

### Claim 43 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The formulation of any one of claims 29 to 42, wherein the formulation further comprises a tonicity modifier, preferably sucrose at a concentration of 8%±1% (w/v).

### Claim 44 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The formulation of any one of claims 29 to 43, wherein the formulation further comprises a surfactant, preferably Polysorbate 80 at concentration of 0.02%±0.01 (w/v).

### Claim 45 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The formulation of any one of claims 29 to 44, wherein the formulation further comprises an antioxidant, preferably L-methionine at a concentration of 0.1%±0.05% (w/v).

### Claim 46 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The formulation of any one of claims 29 to 45 being substantially free of any other additional excipient.

### Claim 47 (depends on 43, 44, 45, 46)

The formulation of any one of claims 43 to 46, which comprises or essentially consists of 20 mg/mL antibody in 20 mM L-histidine/L-histidine monohydrochloride buffer, 8% (w/v), sucrose, 0.1% (w/v) L-methionine and 0.02% (w/v) PS 80 at pH 6.0; preferably wherein the antibody is AP-101.

### Claim 48 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A medicament comprising the formulation of any one of claims 29 to 47, preferably wherein the medicament is for use in the treatment of amyotrophic lateral sclerosis (ALS), most preferably for use in a treatment as defined in any one of the preceding claims.

### Claim 49 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A sterile pharmaceutical container comprising the formulation of any one of claims 29 to 47 or the medicament of claim 48, preferably wherein the container is a single-use glass vial to provide 100 mg of the antibody at a 20 mg/mL concentration, optionally wherein the vial contains an approximate 10% volume overfill.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A method of treatment ALS, wherein the treatment is performed according to any one of claims 1 to 28, or wherein the treatment comprises administering the formulation of any one of claims 29 to 49 or the medicament of claim 48.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

Use of the antibody as defined in any one of the preceding claims or the formulation of claims 29 to 49 for the manufacture of a medicament for the treatment of ALS, wherein the treatment is performed according to any one of claims 1 to 28.
